Stock Events

Stock Events

Medigene 

$2.59
13
+$2.49+2,490% Monday 21:00

Statistics

Day High
0.1
Day Low
0.1
52W High
2.59
52W Low
0.1
Volume
10,000
Avg. Volume
0
Mkt Cap
76.34M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

7AugExpected
Q4 0
Q2 2024
Q4 2024
Q2 2025
-0.54
-0.46
-0.38
-0.3
Expected EPS
N/A
Actual EPS
N/A

Financials

-268.23%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
13.3MRevenue
-35.67MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MDGEF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Immatics N.V
IMTX
Mkt Cap1.24B
Immatics N.V. specializes in TCR therapies targeting cancers, similar to Medigene's core research and product development focus.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in CAR-T cell therapies, a close field to Medigene's TCR-based treatments.
Novartis
NVS
Mkt Cap237.61B
Novartis is a major player in the CAR-T therapy market with approved products, competing in the broader cell therapy market that includes Medigene's TCR therapies.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics is involved in the development of allogeneic CAR-T therapies, a next-generation approach that competes with Medigene's autologous TCR therapies.
Precigen
PGEN
Mkt Cap1.46B
Precigen, Inc. operates in the synthetic biology field, developing CAR-T and TCR therapies among other gene and cell therapies, making it a competitor in the advanced therapy sector.

About

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells in areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
Show more...
CEO
Mr. Ralph Schafer
Employees
87
Country
DE
ISIN
DE000A40ESG2

Listings

OTC Link
US
MDGEF
F
DE
MDG1.F
VI
AT
MDG2.VI

0 Comments

Share your thoughts

FAQ

What is Medigene stock price today?▼
The current price of MDGEF is $2.59 USD — it has increased by +2,490% in the past 24 hours. Watch Medigene stock price performance more closely on the chart.
What is Medigene stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Medigene stocks are traded under the ticker MDGEF.
What is Medigene market cap?▼
Today Medigene has the market capitalization of 76.34M
What is Medigene revenue for the last year?▼
Medigene revenue for the last year amounts to 13.3M USD.
What is Medigene net income for the last year?▼
MDGEF net income for the last year is -35.67M USD.
How many employees does Medigene have?▼
As of April 03, 2026, the company has 87 employees.
In which sector is Medigene located?▼
Medigene operates in the Health Care sector.
When did Medigene complete a stock split?▼
Medigene has not had any recent stock splits.
Where is Medigene headquartered?▼
Medigene is headquartered in Munich, DE.